Current diagnostic testing for prostate cancer relies primarily on measuring serum levels of total prostate-specific antigen (PSA), which can lead to the over-diagnosis and/or overtreatment of prostate cancer [25]. This evidence concerns the gene PROS1 and prostate carcinoma.